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e.2013.04Abstract Background: Psoriasis is a T-cell mediated hyperproliferative cutaneous disease of mul-
tifactorial etiology. Prolactin (PRL) has been implicated in the pathogenesis of psoriasis and several
studies have pointed to a potential therapeutic role of bromocriptine in psoriasis.
Aim: To assess the clinical efﬁcacy of bromocriptine and the inﬂuence of serum prolactin levels on
disease severity in patients with chronic plaque-type psoriasis.
Methods: Forty-ﬁve patients with chronic plaque-type psoriasis and 45 healthy control subjects
were included in the study. The patients were divided into three equal groups; a group treated with
narrow-band ultraviolet B (NB-UVB), a group treated with bromocriptine, and a group treated
with both NB-UVB and bromocriptine. Serum PRL levels and psoriasis area severity index (PASI)
scores were measured before and after a 12-week treatment period.
Results: There was no signiﬁcant difference in the serum PRL levels between the patients prior to
treatment and the controls. Correlations between PASI scores and serum PRL levels before and, narrow-band ultraviolet B;
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386 N.A. AbouKhedr, A.A. Eidafter treatment were insigniﬁcant. Post-treatment PASI scores were signiﬁcantly lower than pre-
treatment values in each of the treated groups. Post-treatment serum PRL levels were signiﬁcantly
lower in both groups receiving bromocriptine than the group receiving NB-UVB alone, they were
also signiﬁcantly lower in the group treated with NB-UVB and bromocriptine than the group trea-
ted with bromocriptine alone.
Conclusions: Bromocriptine may be of value in the treatment of chronic plaque-type psoriasis in
the absence of hyperprolactinemia. NB-UVB may have an additive effect to bromocriptine on
serum PRL levels.
ª 2013 Production and hosting by Elsevier B.V. on behalf of Alexandria University Faculty of Medicine.1. Introduction
Psoriasis is a chronic relapsing T-cell mediated hyperprolifera-
tive cutaneous disease of multifactorial etiology that results
from polygenic predisposition combined with triggering fac-
tors. It affects approximately 2% of the population.1 Clini-
cally, it is characterized by sharply demarcated erythematous
plaques with silvery white scales. Psoriasis can be limited to
the skin or can affect extracutaneous sites such as the joints.
Treatment is tailored according to the patient’s condition
and response to therapy.2
Keratinocyte hyperproliferation and abnormal differentia-
tion, lymphocyte inﬁltration together with various dermal vas-
cular changes are characteristic ﬁndings in psoriasis. T-
lymphocytes and their cytokines and chemokines play an
important role in psoriasis.3
Stress and hormonal factors have been implicated in the
pathogenesis of psoriasis.4 Psoriasis has been reported to wor-
sen at times when hormonal changes such as puberty or men-
opause occur, and may worsen, improve or remain unchanged
during pregnancy and post partum.5 One of the hormones that
has been implicated in the pathogenesis of psoriasis is prolactin
(PRL), which is one of the major hormonal signals that are
upregulated in response to psychological and physical stress.6
PRL was found to have local cytokine-like activities, and to
stimulate the proliferation of human keratinocytes in vitro.7
Bromocriptine is a tetracyclic ergoline compound derived
from plant alkaloids. It is a strong dopamine D2-receptor ago-
nist that inhibits pituitary secretion of PRL. Bromocriptine has
also partial D1-receptor agonist activity, 5-HT2 antagonist ef-
fects and mild adrenergic effects.8 Oral doses of 5.0–7.5 mg/
day typically cause a marked fall in the concentration of circu-
lating prolactin. Higher doses are used to treat acromegaly and
Parkinsonism. Common side effects include nausea, headache,
dizziness and fatigue.9 Several studies demonstrated the bene-
ﬁcial effects of bromocriptine on psoriatic skin lesions,10,11
psoriatic arthritis,12 and autoimmune diseases such as systemic
lupus erythematosus, rheumatoid arthritis, Reiter’s syndrome
and uveitis.13
The aim was to assess the clinical efﬁcacy of bromocriptine
and the inﬂuence of serum prolactin levels on disease severity
in patients with chronic plaque-type psoriasis.
2. Materials and methods
This study was approved by the ethics committee of the Alex-
andria faculty of medicine. An informed consent was signed by
all patients and control subjects prior to participation in the
study.2.1. Participants
Forty-ﬁve patients with chronic plaque-type psoriasis and 45
healthy control subjects were recruited in the study. Exclusion
criteria were pregnancy, lactation, uncontrolled hypertension,
endocrine, renal, hepatic or psychiatric disease.14 Patients
receiving medications known to induce hyperprolactinemia
such as haloperidol, thioridazine, resperidone, clomipramine,
sertraline, ﬂuoxetine, pargyline, buspirone, metoclopramide,
domperidone, alpha-methyldopa, verapamil, cimetidine, rani-
tidine and fenﬂuramine15 were excluded from the study and
so were patients with known hypersensitivity to bromocriptine
or any ergot alkaloid. Patients with serum PRL levels sugges-
tive of prolactinoma (>100 ng/ml) or presenting clinically
with galactorrhea, amenorrhea, impotence, decreased libido,
headache or visual disturbances were also excluded.
No topical or systemic forms of treatment were received by
the patients for a minimum of 2–6 weeks respectively prior to
starting therapy in the study. Patients already receiving treat-
ment for their psoriasis and demonstrating clinical improve-
ment at the time of enrollment were not included in the
study and so were patients with a history of recent acitretin
intake.
Patients were randomly divided into three equal groups; the
ﬁrst group was treated with narrow-band ultraviolet B (NB-
UVB) and received three sessions per week, the second group
received bromocriptine in a dose of 5 mg/day. The third group
received NB-UVB sessions three times per week and bromo-
criptine in a dose of 5 mg/day. Two of the patients receiving
bromocriptine developed mild nausea and one patient devel-
oped headache, but the symptoms were not severe enough to
warrant discontinuation of therapy.
In all three groups, treatment was continued for twelve
weeks. Serum PRL levels were measured and psoriasis area
severity index (PASI) scores were calculated in all patients be-
fore starting therapy and at the end of the 12-week treatment
period.
2.2. Serum PRL measurement
A morning blood sample was taken from the patients under
standardized conditions. In females samples were taken in the
premenstrual phase of the cycle. Quantitative determination
was done in serum using the ADVIA Centaur system, which
is a two-site sandwich immunoassay using direct chemilumino-
metric technology, which uses constant amounts of two anti-
bodies. The ﬁrst antibody, in the Lite Reagent, is a polyclonal
goat anti-prolactin antibody labeled with acridinium ester.
The second antibody, in the Solid Phase, is a monoclonal mouse
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magnetic particles. A direct relationship exists between the
amount of PRL present in the patient sample and the amount
of relative light units detected by the system.
2.3. Psoriasis severity assessment
The degree of disease severity was assessed using PASI score.16
PASI scores were assessed by the same investigator at the
beginning and at the end of the 12-week treatment period.
2.4. Statistical analysis
Data were fed to the computer using IBM SPSS software pack-
age version 20.0. Qualitative data were described using number
and percent. Association between categorical variables was
tested using Chi-square test. When more than 20% of the cells
have expected count less than 5, correction for chi-square was
conducted using Fisher’s Exact test or Monte Carlo correction.
Quantitative data were described as median (min–max), as well
as mean ± standard deviation. For normally distributed data,
parametric tests were applied. If the data were abnormally dis-
tributed, non-parametric tests were used. For normally distrib-
uted data, comparison between two independent populations
was done using independent t-test. When more than two pop-
ulations were analyzed F-test (ANOVA) was used. For abnor-
mally distributed data, Mann–Whitney test was used to
analyze two independent populations. If more than two popu-
lations were analyzed Kruskal–Wallis test was used. Wilcoxon
signed-rank test was used to compare between the different
periods. Correlations between two quantitative variables were
assessed using Spearman coefﬁcient. Signiﬁcance test results
are quoted as two-tailed probabilities. Signiﬁcance of the ob-
tained results was judged at the 5% level.
3. Results
No signiﬁcant differences were found between patients and
controls regarding the age (p= 0.138), sex (p= 0.109), skin
type (p= 0.969) and serum PRL (p= 0.460). Patients were
randomly divided into three equal groups. In all three groups,
patients were age (p= 0.125), sex (p= 0.910) and skin type
(p= 0.909) matched.
3.1. Serum PRL levels and disease severity
None of the patients participating in this study had serum PRL
levels exceeding the reference range values (non pregnantTable 1 Pre- and post-treatment serum PRL levels in the treated g
Narrowband
group (n= 15)
Bro
gro
Pre-treatment Prolactin (ng/ml) 6.7 (2.7–11.4) 7.5
Post-treatment Prolactin (ng/ml) 6.8 (5.0–15.0) 4.9
p2 0.078 0.00
p1: p value for Kruskal Wallis test.
p2: p value for Mann–Whitney test.
Data are expressed as median (min–max).
* Statistically signiﬁcant at p 6 0.05.females: 2.8–29.2 ng/ml, males: 2.1–17.7 ng/ml). There was
no signiﬁcant difference in the pre-treatment serum PRL levels
among the psoriatic groups (p= 0.744) (Table 1). Correlations
between PASI scores and serum PRL levels before
(r= 0.048, p= 0.755) and after treatment (r= 0.211,
p= 0.450 in the group treated with NB-UVB, r= 0.232,
p= 0.405 in the group treated with bromocriptine, and
r= 0.132, p= 0.638 in the group treated with both NB-
UVB and bromocriptine) were statistically insigniﬁcant.
3.2. Effect of therapy on serum PRL levels
The post-treatment PRL levels were signiﬁcantly lower than
the pre-treatment levels in the groups receiving bromocriptine
(p= 0.001). Post-treatment serum PRL levels were signiﬁ-
cantly lower in both groups receiving bromocriptine
(p< 0.001) than the group treated with NB-UVB alone. The
group receiving NB-UVB and bromocriptine had signiﬁcantly
lower post-treatment serum PRL levels than the group treated
with bromocriptine alone (p< 0.001) (Table 1).
3.3. Effect of therapy on disease severity
There was no signiﬁcant difference in the pre- or post-treat-
ment PASI scores (p= 0.073, 0.345, respectively) among the
psoriatic groups. Post-treatment PASI scores were signiﬁcantly
lower than pre-treatment values in each of the three treated
groups (Table 2). There was also no signiﬁcant difference in
the number of responders and non-responders among the trea-
ted groups (p= 0.104) (Table 3). There was, however, a trend
toward signiﬁcance (p= 0.55) on comparing the number of
responders and non-responders in the group treated with bro-
mocriptine alone and the group treated with both NB-UVB
and bromocriptine.
4. Discussion
Several studies have pointed to the possible role of PRL in the
pathogenesis of psoriasis. Some authors found serum PRL lev-
els to be signiﬁcantly higher in psoriatic patients compared to
normal control subjects,17,18 some psoriatic patients were even
found to be hyperprolactinemic.17 A signiﬁcant correlation be-
tween serum prolactin levels and PASI scores was also de-
tected, suggesting that PRL may serve as a useful marker for
disease activity.18 Other investigators, however, did not ﬁnd
a correlation between serum PRL levels and PASI scores,
nor did they ﬁnd serum PRL levels to be signiﬁcantly higher
in psoriatic patients compared to healthy controls.19,20roups.
mocriptine
up (n= 15)
NB-UVB + bromocriptine
group (n= 15)
p1
(3.2–13.3) 7.2 (3.8–13.9) 0.744
(1.3–12.2) 1.8 (0.70–4.0) <0.001*
1* 0.001*
Table 2 Pre- and post-treatment PASI scores in the treated groups.
Narrowband group (n= 15) Bromocriptine group (n= 15) NB-UVB+ bromocriptine group (n= 15) p1
Pre-treatment PASI 19.1 (11.7–31.8) 18.7 (13.7–31.9) 24.0 (12.7–35.7) 0.073
Post-treatment PASI 7.2 (2.5–23.1) 12.7 (1.6–24.5) 11.6 (5.9–37.8) 0.345
p2 0.003* 0.005* 0.006*
p1: p value for Kruskal Wallis test.
p2: p value for Mann–Whitney test.
Data are expressed as median (min–max).
* Statistically signiﬁcant at p 6 0.05.
Table 3 The number of responders and non-responders in the treated groups.
Narrowband group (n= 15) Bromocriptine group (n= 15) NB-UVB + bromocriptine group (n= 15) p
PASI reduction
<50% 4 (26.7) 5 (33.3) 0 (0.0) 0.104
P50% 9 (60.0) 6 (40.0) 11 (73.3)
Deteriorated cases 2 (13.3) 4 (26.7) 4 (26.7)
Data are expressed as number (percent).
p value for comparing NB-UVB group and bromocriptine group = 0.634.
p value for comparing NB-UVB group and NB-UVB+ bromocriptine group = 0.133.
p value for comparing bromocriptine group and NB-UVB + bromocriptine group = 0.055.
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scores and PRL levels in lesional and non-lesional skin. They
found, however, PRL levels in lesional skin to be signiﬁcantly
higher than non-lesional skin and serum of psoriatic patients,
which led to the assumption that locally produced PRL in pso-
riasis lesions rather than circulating PRL levels may play a role
in the pathogenesis of psoriasis.20 In our study none of the pa-
tients were hyperprolactinemic. Serum PRL levels were not
signiﬁcantly higher in psoriatic patients compared to control
subjects. We did not ﬁnd a signiﬁcant correlation between
PASI scores and serum PRL levels before or after treatment.
These ﬁndings led us too to question the hypothetical role of
circulating PRL in the pathogenesis of psoriasis and its value
as a marker for disease activity.
Bromocriptine has long been investigated for its immuno-
suppressive properties, which may be related to its ability to
lower circulating PRL levels or to its direct suppressive effect
on B and T cells.21,22 Several studies reported the efﬁcacy of
bromocriptine in the treatment of psoriasis10,23 and psoriatic
arthritis.12,24 Bromocriptine was also reported to improve pso-
riasis in three patients whose disease worsened with the devel-
opment of prolactinoma and relapsed when bromocriptine was
discontinued.11 It was also reported to improve psoriatic
arthritis in a case of hyperprolactinemia.25 In our study we
found bromocriptine, either alone or in association with NB-
UVB, to be effective but not superior to NB-UVB in the treat-
ment of chronic plaque-type psoriasis. We found it to be effec-
tive in the absence of hyperprolactinemia. The signiﬁcantly
lower post-treatment serum PRL levels in the group treated
with NB-UVB and bromocriptine than the group treated with
bromocriptine alone suggests an additive effect of NB-UVB to
bromocriptine on serum PRL levels.
5. Conclusion
Our data suggest that bromocriptine may have a role in the
treatment of chronic plaque-type psoriasis in the absence ofhyperprolactinemia, and that NB-UVB may have an additive
effect to bromocriptine on serum PRL levels. We did not ﬁnd
bromocriptine or the combination of NB-UVB and bromo-
criptine to be superior to NB-UVB in the treatment of psoria-
sis, nor did we ﬁnd a correlation between serum PRL levels
and disease severity. Further placebo-controlled studies of
longer duration and with larger sample size are required to
conﬁrm our ﬁndings.
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